Hanover - Delayed Quote EUR

Moderna Inc (0QF.HA)

24.37

+0.10

+(0.39%)

At close: April 30 at 5:25:29 PM GMT+2

Wayfair beats, Estee Lauder outlook, Moderna: Trending Tickers

Wayfair (W) stock gains after reporting a surprise earnings beat, with the company saying its business model should minimize tariff impacts. Estee Lauder (EL) warns of a slowdown in sales in 2025 but expects a return to growth in 2026, assuming there is more clarity on Trump's tariff policies. Moderna (MRNA) announces plans to cut $1.5 billion after reporting a 35% drop in revenue from the year-ago period. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 14 hours ago

W

EL

MRNA
Q1 2025 Moderna Inc Earnings Call

Q1 2025 Moderna Inc Earnings Call

Thomson Reuters StreetEvents 1 hour ago

MRNA
Moderna Cuts Costs as COVID Sales Slump

Trims 2026 operating expenses by up to $500M after Q1 revenue plunges 35% to $108M

GuruFocus.com 10 hours ago

MRNA
Moderna combination flu, COVID shot delayed amid FDA scrutiny

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

BioPharma Dive 13 hours ago

MRNA
Moderna First-Quarter Loss Unexpectedly Improves Even as Revenue Drops

Moderna's (MRNA) first-quarter loss unexpectedly improved year on year as a drop in expenses helped

PREMIUM
MT Newswires 13 hours ago

MRNA
Moderna Shares Drop As Political Picture Worsens

Moderna laid out plans Thursday to slash future costs in an effort to stop bleeding cash, but a worsening political environment for vaccine companies is making its plan a tough sell. Moderna stuck by its prior guidance and reported a quarterly loss of $2.52 a share; the consensus estimate was a per-share loss of $3.12. Revenue was $108 million, in line with the $106 million consensus estimate.

Barrons.com 14 hours ago

MRNA
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.

Zacks 14 hours ago

MRNA
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline

Moderna stock crumbled Thursday after the biotech company missed sales estimates for its two products, Spikevax and mResvia.

Investor's Business Daily 16 hours ago

MRNA
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 13.70% and 14.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 18 hours ago

MRNA
Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its GAAP loss of $2.52 per share was 18.6% above analysts’ consensus estimates.

StockStory 19 hours ago

MRNA
Moderna Posts Loss, Citing Seasonality of Respiratory Business

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.

The Wall Street Journal 19 hours ago

MRNA
Moderna: Q1 Earnings Snapshot

MRNA) on Thursday reported a loss of $971 million in its first quarter. The Cambridge, Massachusetts-based company said it had a loss of $2.52 per share. The results topped Wall Street expectations.

Associated Press Finance 19 hours ago

MRNA
Moderna says FDA has been constructive, but delays flu/COVID shot

(Reuters) -Moderna on Thursday pushed back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza, but said exchanges with U.S. drug regulators have remained constructive under Health Secretary and vaccine skeptic Robert F. Kennedy Jr. The U.S. vaccine maker reported first-quarter profit and sales that beat Wall Street estimates, as the company's cost-cutting efforts offset some of the waning post-pandemic demand for its COVID shot. The company's shares, which have been battered by declining COVID revenue as well as political concerns spurred by Kennedy's appointment, fell 3.3% to $27.60 in morning trading.

Reuters 19 hours ago

MRNA
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of ...

ACCESS Newswire 19 hours ago

MRNA
Moderna, Inc. (MRNA): Among the Worst Performing Stocks in S&P 500 So Far in 2025

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for the broad market index since […]

Insider Monkey yesterday

MRNA

^GSPC
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

StockStory yesterday

MRNA

ABBV
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

MRNA
Down 36%, Is Moderna a Buy on the Dip?

With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention. This doesn't mean Moderna is inactive; in fact, it's quite the opposite. Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Motley Fool 3 days ago

MRNA
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals (NASDAQ: REGN) and Moderna (NASDAQ: MRNA). Moderna made a name for itself by quickly developing and marketing an effective COVID-19 vaccine when the world needed it most. Moderna's revenue declined substantially while it returned to being unprofitable.

Motley Fool 5 days ago

MRNA

REGN
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.

Zacks 6 days ago

MRNA

Performance Overview

Return	0QF.HA	S&P 500 (^GSPC)
YTD	-36.20%	-4.72%
1-Year	-76.68%	+11.67%
3-Year	-81.85%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna Inc (0QF.HA)

Wayfair beats, Estee Lauder outlook, Moderna: Trending Tickers

Q1 2025 Moderna Inc Earnings Call

Moderna Cuts Costs as COVID Sales Slump

Moderna combination flu, COVID shot delayed amid FDA scrutiny

Moderna First-Quarter Loss Unexpectedly Improves Even as Revenue Drops

Moderna Shares Drop As Political Picture Worsens

Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline

Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates

Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates

Moderna Posts Loss, Citing Seasonality of Respiratory Business

Moderna: Q1 Earnings Snapshot

Moderna says FDA has been constructive, but delays flu/COVID shot

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

Moderna, Inc. (MRNA): Among the Worst Performing Stocks in S&P 500 So Far in 2025

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for

Down 36%, Is Moderna a Buy on the Dip?

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Performance Overview